Top

Published in:

01-02-2010

Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome

Author: Ricard Cervera

Published in: Current Rheumatology Reports | Issue 1/2010

Abstract

The catastrophic antiphospholipid syndrome (APS) is a potentially life-threatening condition, the diagnosis of which requires a high degree of clinical awareness on the part of attending physicians. Patients with APS present with 1) clinical evidence of multiple organ involvement developed over a very short time; 2) histopathologic evidence of multiple small-vessel occlusions; and 3) laboratory confirmation of the presence of antiphospholipid antibodies, usually in high titer. A combination of anticoagulants, corticosteroids, intravenous immunoglobulins, and plasma exchanges is the basic treatment for all patients with this severe condition. Unfortunately, despite current therapies, the mortality rate is still high (around 30%). However, once patients with catastrophic APS have recovered, they usually follow a stable course with continued anticoagulation and few patients present with a relapse of the catastrophic episode.

Asherson RA: The catastrophic antiphospholipid antibody syndrome. J Rheumatol 1992, 19:508–512.PubMed

Piette JC, Cervera R, Levy R, et al.: The catastrophic antiphospholipid syndrome—Asherson’s syndrome. Ann Med Intern 2003, 154:95–96.

Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antibody syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998, 77:195–207.CrossRef

Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001, 80:355–376.CrossRef

Bucciarelli S, Espinosa G, Cervera R, et al.: Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006, 54:2568–2576.CrossRefPubMed

Cervera R, Piette JC, Font J, et al.: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019–1027.CrossRefPubMed

Asherson RA, Cervera R, de Groot P, et al.: Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12:530–534.CrossRefPubMed

Cervera R, Font J, Gómez–Puerta JA, et al.: Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005, 64:1205–1209.CrossRefPubMed

•• Cervera R, Bucciarelli S, Plasín MA, et al.: Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009, 32:240–245. This article discusses the largest series (n = 280) of patients with catastrophic APS.CrossRefPubMed

10.

Espinosa G, Cervera R, Asherson RA: Catastrophic antiphospholipid syndrome and sepsis: a common link? J Rheumatol 2007, 34:923–926.PubMed

11.

Cervera R, Font J, Tincani A, Boffa MC: V Meeting of the European Forum on Antiphospholipid Antibodies. Autoimm Rev 2006, 5:499–507.CrossRef

12.

Asherson RA, Espinosa G, Menahem S, et al.: Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008, 37:366–372.CrossRefPubMed

13.

Gómez–Puerta JA, Cervera R, Espinosa G, et al.: Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007, 66:740–746.CrossRefPubMed

14.

Miesbach W, Asherson RA, Cervera R, et al.: The role of malignancies in patients with catastrophic antiphospholipid (Asherson’s) syndrome. Clin Rheumatol 2007, 26:2109–2114.CrossRefPubMed

15.

Cervera R, Espinosa G, Cordero A, et al.: Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. Semin Arthritis Rheum 2007, 36:287–296.CrossRefPubMed

16.

Belmont HM, Abramson SB, Lie JT: Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996, 39:9–22.CrossRefPubMed

17.

Bucciarelli S, Espinosa G, Asherson RA, et al.: The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Ann Rheum Dis 2006, 65:81–86.CrossRefPubMed

18.

Asherson RA, Espinosa G, Cervera R, et al.: Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 2005, 64:943–946.CrossRefPubMed

19.

Espinosa G, Bucciarelli S, Cervera R, et al.: Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004, 63:730–736.CrossRefPubMed

20.

Asherson RA, Cervera R, Font J: Multiorgan thrombotic disorders in systemic lupus erythematosus: a common link? Lupus 1992, 1:199–203.CrossRefPubMed

21.

Asherson RA, Pierangeli SS, Cervera R: Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis 2007, 66:429–432.CrossRefPubMed

22.

Asherson RA, Pierangeli SS, Cervera R: Microangiopathic antiphospholipid-associated syndromes revisited: new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 2007, 34:1793–1795.PubMed

23.

Asherson R, Cervera R: Microvascular and microangiopathic antiphospholipid-associated syndromes (MAPS): semantic or antisemantic? Autoimm Rev 2008, 7:164–167.CrossRef

24.

Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222–1226.CrossRefPubMed

25.

Christman JW, Lancaster LH, Blackwell TS: Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998, 24:1131–1138.CrossRefPubMed

26.

Uthman I, Shamseddine A, Taher A: The role of therapeutic plasma exchange in catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005, 33:11–17.CrossRefPubMed

27.

Orbach H, Katz U, Sherer Y, Shoenfeld Y: Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29:173–184.CrossRefPubMed

28.

Bayraktar UD, Erkan D, Bucciarelli S, et al.: The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007, 34:346–352.PubMed

29.

Tenedious R, Erkan D, Lockshin MD: Rituximab in the primary antiphospholipid syndrome [abstract]. Arthritis Rheum 2005, 52:4078.

30.

Erdozain JG, Ruiz–Irastorza G, Egurbide MV, et al.: Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome [abstract]. Haematologica 2004, 89:ECR34.PubMed

31.

Rubenstein E, Arkfeld DG, Metyas S, et al.: Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006, 33:355–357.PubMed

32.

Dosekun AK, Pollak VE, Glas–Greenwalt P, et al.: Ancrod in systemic lupus erythematosus with thrombosis: clinical and fibrinolysis effects. Arch Intern Med 1984, 144:37–42.CrossRefPubMed

33.

Yang LH, Hoppensteadt DA, Iqbal O, Fareed J: Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings. Thromb Res 1996, 84:167–177.CrossRefPubMed

34.

Vero S, Asherson RA, Erkan D: Critical care review: catastrophic antiphospholipid syndrome. J Intensive Care Med 2006, 21:144–159.CrossRef

35.

Bucciarelli S, Erkan D, Espinosa G, Cervera R: Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clinic Rev Allerg Immunol 2009, 38:80–84.CrossRef

36.

Erkan D, Asherson RA, Espinosa G, et al.: The long-term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003, 62:530–533.CrossRefPubMed

37.

Bucciarelli S, Espinosa G, Bové A, et al.: Relapsing catastrophic antiphospholipid syndrome [abstract]. Ann Rheum Dis 2007, 66:304.

Title: Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome
Author: Ricard Cervera
Publication date: 01-02-2010
Publisher: Current Science Inc.
Published in: Current Rheumatology Reports / Issue 1/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-009-0073-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Intensity of Warfarin Coagulation in the Antiphospholipid Syndrome

Use of Rituximab in the Antiphospholipid Syndrome

Molecular Pathogenesis of Skin Fibrosis: Insight from Animal Models

The Roll of Toll-like Receptors in the Antiphospholipid Syndrome

Impaired Fibrinolysis in the Antiphospholipid Syndrome

The Current State of Biomarkers in Systemic Sclerosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page